Daniel L. Kaufman

Dr. Daniel L. Kaufman is a Professor in the Department of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA) School of Medicine. His research focuses on immunotherapeutics for autoimmune diseases, particularly type 1 diabetes (T1D), multiple sclerosis, Parkinson's disease, and neuroinflammation associated with long COVID. He has pioneered the use of GABA receptor agonists to modulate immune responses and promote beta-cell survival.

• Academic Affiliation: UCLA School of Medicine
• Research Focus: Autoimmune disease, neuroinflammation, immunotherapy, GABA signaling

Research Interests:
Dr. Kaufman's work bridges immunology and neuroscience, exploring how GABA receptors regulate T cell autoimmunity and inflammatory responses. His lab has developed therapies targeting the GABA-receptor system for T1D, multiple sclerosis, and SARS-CoV-2 infections, with several approaches now in clinical trials.

Scientific Trends:
Recent articles emphasize GABA's role in:

• Neuroimmune regulation
• Anti-inflammatory immunotherapy
• Long COVID pathogenesis
• Glioblastoma immune evasion
• Beta-cell survival
• Coronavirus pathogenesis

Research Funding:
NIH grants (R21DE029020, R21TR001742, R21AI119831, R01DK092480) have funded his work on GABA-based therapies for Sjogren's syndrome, type 1 diabetes, and neuroinflammation.